LifeSci Capital initiated coverage of Tectonic Therapeutic (TECX) with an Outperform rating and $87 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECX:
- Tectonic Therapeutic Reports Q1 2025 Financial Results
- Promising Phase 1b Results and Market Potential Drive Buy Rating for Tectonic Therapeutic’s TX45
- Tectonic Therapeutic Announces Phase 1b Trial Results
- Promising Phase 1b Results and Favorable Safety Profile Justify Buy Rating for Tectonic Therapeutic
- Tectonic Therapeutic price target raised to $85 from $51 at Mizuho